GODALMING-based Sinclair Pharma has taken a significant step forward in its goal of becomming a leading international speciality pharmaceutical company.

The company’s annual report revealed that the sales and marketing operations have expanded significantly through the acquisition of CS Dermatologie (CSD) and a number of distribution partnerships boosting turnover by 67% to £11.6 million up from the previous years figure of £7 million.

It means the company has achieved organic growth of its product sales of 58% particularly for its main products Atopiclair, a product used in the treatment of eczema and atopic dermatitis, Decapinol for gum disease and Aloclair for mouth ulcers. Sinclair Pharma has proven expertise in acquiring innovative products in niche therapeutic areas such as dermatology and oral health which are late in the development cycle and undervalued.

It applies a regulatory expertise to gain registration for these products so that their commercial potential can be realised. To date, it has acquired one company in the UK, Ashbourne Pharmaceuticals, two companies in Sweden, two in Italy and one with operations in France, Spain and Portugal.

“Since the year end, Sinclair has made continued commercial, regulatory and financial progress with sales of Sinclair’s products continuing to grow,” said its CEO Dr Michael Flynn.

“We announced following the preliminary results that Sinclair had acquired Ashbourne Pharmaceuticals Ltd, the UK sales and marketing company.

“This is a further step towards Sinclair’s goal of building our own sales forces in the main European territories. Integration of both Ashbourne and CSD is proceeding according to plan.”

“Reflecting our enlarged commercial presence in the key European markets and associated investor in Europe, we are now seeking to move from AIM onto the official list of the London Stock Exchange and to seek a secondary listing on the Euronext market in Paris. “Both listings will be through an introduction of shares and new funds will be raised.”